Atopic Dermatitis Immunosuppressive Drugs and Efficacy With COVID-19 Vaccine
In a recent study, researchers attempted to investigate the frequency, determinants, and efficacy of COVID-19 vaccination among patients with atopic dermatitis (AD). The researchers concluded that in patients with AD, COVID-19 vaccination is very effective for a broad range of COVID-19–related outcomes, and the use of immunosuppressive drugs did not impair the effectiveness of the mRNA vaccines in preventing SARS-CoV-2 infection. Read more.
|
Moderna Files for EUA for Pediatric mRNA Vaccine Moderna, Inc., recently announced that it completed its submission for a request for emergency use authorization (EUA) to the FDA for its COVID-19 vaccine (mRNA-1273) in pediatric patients aged 6 months to younger than 2 years and patients aged 2 years to younger than 6 years. Comparable requests are underway with international regulatory authorities. Read more.
|